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The tumor microenvironment (TME) of head and neck squamous cell carcinoma (HNSCC) iscomprised of cancer-a
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Seminarsssociated fibroblasts (CAFs), immune cells, and other supporting cells.
carcinoma cells, such as alterations to TP53, NOTCH1, and specific gene
ntribute to derangements in cancer and microenvironment cells such as
oduction of cytokines, and epithelial to mesenchymal transition (EMT).
ost critical elements of the TME contributing to proliferation, invasion, and
e immune response is suppressed in HNSCC through overexpression of
poptosis of T cells, and alterations in antigen processing machinery.
ical cytokines, such as transforming growth factor-β (TGF-β), contributes
ression, and evolution of CAFs. Inflammation and hypoxia are driving
is and altered metabolism. HNSCC utilizes glycolytic and oxidative
morigenesis via coupled mechanisms between cancer cell regions and
eased understanding of the TME in HNSCC illustrates that the long-held
mucosa” reflects a process that extends beyond the epithelial cells to the
d of each of these elements.
34 & 2014 Elsevier Inc. Open access under CC BY-NC-ND license.S
quamous cell carcinoma comprises more than
90% of cancers of the head and neck and arises
from the squamous lining of the mucosal surfa-
ces of the upper aerodigestive tract, including the oral
cavity, pharynx, larynx, and sinonasal tract. Head and
neck squamous cell carcinoma (HNSCC) is the sixth
most common cancer worldwide, and only 50%–60%
of patients are alive at 5 years after diagnosis.1,2
Treatment can be quite morbid and result in significant
functional as well as aesthetic deficits, such as impair-
ment of speech and swallowing and facial deformity.evier Inc.
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Open access under CC BY-NC-ND license.Treatment failure and locoregional recurrence are
common and occur in up to 30% of patients and
account for the majority of deaths.3 The high rate of
local recurrence produced the long-held notion of
“condemned mucosa” or “field cancerization” initially
described in the 1950s.4 This concept underscores not
only the difficulty in treating HNSCC but also denotes
the complexity of the molecular conditions under
which HNSCC develops and recurs. It is clear that
the notion of the condemned mucosa reflects a
“condemned tissue” composed of the cancerous cells,
adjacent epithelial, stromal, and immune cells and their
surrounding matrix. Together these elements comprise
the tumor microenvironment (TME). In fact, this shift
in thought from the concept that cancer is derived
from a single cell type, to a disease occurring in a
complex tissue, has led some investigators to suggest
that the very definition of carcinoma be changed.5
Tumorigenesis requires multiple elements outlined
by Hanahan and Weinberg: (1) limitless replicative
potential, (2) self-sufficiency in growth signals, (3) insen-
sitivity to anti-growth signals, (4) ability to evade
apoptosis, (5) increased angiogenesis, and (6) invasion
and metastasis.6 Knowledge of the mechanisms
through which the cancer cells use the TME to execute
these processes continues to evolve.7,8 There is great
interest in the downstream paracrine interactions with217
J.M. Curry et al218the stroma, immune interactions, and metabolic
changes and the role each plays in tumorigenesis.
HNSCC is genetically heterogeneous, but a num-
ber of pathways have been found to be commonly
involved; the impact of several critical abnormalities
on the TME is highlighted below. The cellular
elements of the TME often coevolve with the tumor.
Stromal fibroblasts, T cells, macrophages, and other
cell types develop abnormal phenotypes in a disor-
ganized response to the cancer (Figure 1). These non-
cancerous cells provide many of the paracrine signals
necessary to turn on the pleotrophic abilities of
cancer cells.9 For example, fibroblasts become
cancer-associated fibroblasts and secrete factors such
as matrix metalloproteins (MMPs), contributing to
tumor invasiveness. Furthermore, as the chronic
inflammation of the TME remains unresolved, alter-
ations in adaptive immune response such as apopto-
sis of cytotoxic T cells and activation of suppressor T
cells occurs.10 Additionally, tumors reprogram their
surroundings creating a metabolically fertile environ-
ment to meet their high energy and anabolic require-
ments. This process was aptly described by Paget as
the “seed and soil” hypothesis.11 Fundamental tumor–
non-tumor microenvironmental interactions such as
these represent potential points of intervention for
therapeutic strategies. Many critical targets, such as
nuclear factor-κB (NF-κB), hypoxia-inducible factor
(HIF)-1α, and vascular endothelial growth factor
(VEGF), have been, and continue to be, explored as
therapeutic targets in the TME12–14 (Table 1).IMPACT OF GENETIC AND EPIGENETIC
CHANGES OF THE EPITHELIUM ON THE TME
The initiating genetic alterations in the epithelial
cells of HNSCC are primarily the result of the
carcinogenic properties of tobacco and alcohol, and
in the oropharynx, oncogenic strains of the human
papilloma virus (HPV). Classically, HNSCC has been
thought of as a disease caused by tobacco and
alcohol, yet tobacco-related cancers are decreasingFigure 1. Select elements and interaciotns of the TME. The
perivascular niche that commonly contain cancer stem cells an
compartment contains tumor cells that are glycolytic and less pro
DDR is shown between the leading edge tumor edge and norma
adjacent to normal stroma and ﬁbroblasts (yellow). CAFs expre
protein inducer (EMMPRIN) on cancer cells to activate MMP2
activate TGF-β. CAFs and tumor cells produce elements like VEG
interactions between regulatory T cells (pink), cytotoxic T cells (r
(blue/green) are shown. TGF-β and IL-10 produced by TAMs an
MIF that recruits neutrophils. Regulatory T cells induce tolera
cytotoxic T cells in utlitzed by cancer cells to induce apoptos
increase angiogenesis and invasion by production of MMP-9, V
orange) are recruited to the TME by GM-CSF produced by canc
TGF-β.in incidence.15 Over the past several decades, onco-
genic strains of HPV have become apparent as an
etiology for oropharyngeal squamous cell carcinoma
(OPSCC). HPV-related OPSCC accounts for up to 60%
of cases of oropharyngeal cancer in some regions;
this has resulted in an increased incidence among
younger nonsmokers, and has been equated to an
epidemic by some investigators.16 Currently, this is
the second most common malignancy caused by
HPV.17 OPSCC is caused primarily by HPV16 (but
also HPV18, HPV31, and others), via the E6 and E7
mechanisms established in cervical cancer.18
The most widely identified mutation in non–HPV-
related HNSCC occurs in the tumor-suppressor gene
TP53. This has been identified to occur in approx-
imately 50% of HNSCCs and is likely an early event, as
it is commonly found in premalignant lesions as
well.19–21 Mutations also have been shown to corre-
late with aggression and poor outcomes; for exam-
ple, p53 mutations have been found in 95% of
radioresistant tumors.22–24 Histologically negative
margins with p53 mutations have been shown to be
associated with a greater incidence of local recur-
rence.25 Mutation of TP53 in tumor cells is associated
with increased migration of cancer-associated fibro-
blasts (CAFs) to the TME, while intact TP53 inhibits
migration.26 Loss of functional p53 increases reactive
oxygen species (ROS) and reactive nitrogen species
(RNS) and may drive carcinogenesis via NF-κB and
other inflammatory-mediated mechanisms. Altera-
tions in TP53 induce a DNA damage response
(DDR) in adjacent non-tumoral cells via production
of ROS. This effect was recently demonstrated in
esophageal SCC, and it increases with proximity to
and size of the primary tumor, with effects being
identified several centimeters from the tumor.27–30
TP53 mutations also have been linked to abnormal
tumor metabolism, contributing to the Warburg
effect through increased activity of glucose trans-
porters and glycolytic enzymes furthering the pro-
duction of an acidic environment and high levels of
ROS toxic to normal cells31 (Figure 1).tumor is shown here with the leading tumor edge and
d highly replicating tumor cells (blue). The more central
liferative (orange). Peritumoral epithelium demonstrating
l epithelium. CAFs (purple) are shown in the tumor stroma
ss MT-MMP that interacts with extrcellular metallomatrix
. CSCs express CD144, which interacts with MMP9 to
F, PGE2, and CXCL12 that trigger angiogenesis. Immune
ed), M2 TAMs (green), and tumor-associated neurtrophils
d cancer cells suppress T-cell activity. TAMs also produce
nce by cytotoxic T cells. The Fas receptor on activated
is. Tumor-associated neutrophils produce ROS, and also
EGF, and HGF. CD34þ myeloid progenitor cells (yellow/
er cells which in turn induce immunosuppression through
Tumor microenvironment in HNSCC 219NOTCH1, the second most commonly mutated
gene in HNSCC occurring in approximately 15% of
cases, functions as a tumor-suppressor.21 It encodes a
transmembrane receptor that regulates cell differ-
entiation and embryonic development.21,32 In
HNSCC, it is dependent on intercellular signaling inthe TME and contributes to proliferation and invasive-
ness through the pro-inflammatory cytokine, tumor
necrosis factor-α (TNF-α). This TNF-α mechanism acts
on Slug and Twist, two other important transcription
factors that act as regulators of invasion and epithelial
to mesenchymal transition (EMT).9,33 Evidence also
Table 1. Critical Cells of the TME in HNSCC
Cell Type Markers Secreted Factors Metabolism References
Squamous Cell Carcinoma
Key Genetic Alterations: TP53,
NOTCH1, EGFR, CDKN2a, STAT3,
Cyclin D1, Rb
E-cadherin, cytokeratins,
PD-L1, FasL
MMP 2, MMP 9, MMP 13,
ROS,VEGF, CXCL1,
CXCL8, PDGF, IL-8,
FGF-2, TGF-β, TNF-α,
IL-1, GMCSF
Tan et al,
Koontongkaew S,
Zhang Z et al,
Smith A et al,
Curry J et al, Feron O.
Central tumor compartment Glycolytic: (MCT4þ,
MCT1, TOMM20,
COX)
OXPHOS: (MCT1þ,
MCT4-,TOMM20þ,
COXþ)
Leading edge/invasive front,
perivascular niche (proliferative
cancer cells: high Ki-67)
Cancer stem cells CD33, CD144, ALDH
Epithelial to mesenchymal
transition
N-cadherin, vimentin
Cancer-Associated Fibroblast α-SMA, integrin α6 HGF, CXCL12, TGF-β,
MMP2, MMP9, PMF,
PDGF, Type IV collagen,
Col15-binding integrins,
PGE2
Glycolytic: (MCT4þ,
MCT1-LDH-Bþ)
Leef G, Curry J et al,
Wheeler SE et al,
Marsh D et al
Tumor-Inﬁltrating Lymphocytes
Regulatory T cells CD4þCD25þFoxP3þ IL-10, IL 12, TGF-β Young MR, Ferris RL
et al, Whiteside TLCytotoxic T cells CD8þ, TCR, Fas, PD-1 Perforin, granzymes,
granulysin
Th2 suppressor cells CD4þ IL-4, IL-6, IL-10
Myeloid progenitor cells CD34þ TGF-β
Tumor-Associated Macrophages
(M2)
IL-10, TGF-β, MIF, EGF, CSF-
1, MMP9, CXCL2,CXCL8,
VEGF, ROS, RNS, PGEs
Lago Costa N et al,
Dumitru C et al,
Galdiero MR et al
Tumor-Associated Neutrophils MMP9, VEGF, HGF, elastase,
ROS, PGEs
Galdiero MR et al,
Dumtru C et al
Endothelial Cells Endothelins, CXCL1, CXCL8 Neiva KG et al
Abbreviations: Rb, retinoblastoma gene; EGFR, epidermal growth factor receptor; CDKN2a, cyclin-dependent kinase inhibitor 2a; STAT 3, signal transducer and activator of transcription 3;
PD-L1, programmed death ligand-1; FasL, Fas ligand; MMP, matrix metalloprotein; ALDH, aldehyde dehydrogenase; ROS, reactive oxygen species; VEGF, vascular endothelial growth
factor; IL, inteleukin; FGF,ﬁbroblast growth factor; TGF-β, transforming growth factor-β; TNF-α, tumor necrosis factor-α; PDGF, platelet-derived growth factor; GM-CSF, granulocye-
macrophage colony-stimulating factor; EGF, epidermal growth factor; CSF-1, colony-stimulating factor-1; TCR, T-cell receptor; FoxP3, forked/winghead transcription factor; RNS, reactive
nitrogen species; MCT, monocarboxylate transporter; PGE, protaglandin; PD-1, programmed death-1; TOMM20, translocase of outer mitochondrial membrane 20; COX, cytochrome C
oxidase complex; LDH-B, lactate dehydrogenase B.
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Tumor microenvironment in HNSCC 221has suggested that its activity is mediated through
MMPs and the inflammatory transcription factor, NF-
κB, among other critical mechanisms34,35 (Figure 1).
EGFR is a membrane-bound tyrosine kinase recep-
tor that binds epidermal growth factor (EGF) and TGF-
α. It is the target for the effective and widely used
monoclonal antibody, cetuximab. Mutation of the
EGFR gene is only present in about 10% of cases,
but gene amplification is present in about 30% of cases
and overexpression has been identified in up to 90%
of cases. Increased expression and gene copy number
correlate with poor prognosis.36–39 After binding
one of its ligands, EGFR triggers multiple intracellular
signaling cascades that activate cell proliferation,
survival, invasion, metastasis, and angiogenesis.21,40–43
It also allows for decreased response to radiotherapy
by enhancing proliferation, DNA-repair, and hypoxic
responses within the TME.44–46 Activation triggers
increased interleukin-8 (IL-8) and VEGF production,
promoting inflammation and angiogenesis.47,48
Cyclin-dependent kinase inhibitor 2a (CDKN2a) is
an important tumor-suppressor that is mutated in
9%–12% of HNSCC patients. The function of its
product, p16, is to block cell cycle progression from
the G1 to S phase, and is typically upregulated under
stress conditions in the cellular microenvironment
such as hypoxia.49 Mutations are common but alone
likely to be insufficient to result in tumorigenesis.21
Mutational loss of function correlates with a wors-
ened prognosis, while overexpression of p16 is
common in HPV-related OPSCC and correlates with
an improved prognosis.45,48,50
Signal transducer and activation of transcription
(STAT) proteins are transcription factors that are
commonly overexpressed in cancer, and in HNSCC,
STAT3 has been found to be commonly mutated and
overexpressed.5 STAT3 activation is linked to numer-
ous pathways, including TGF-β, IL-6, and EGFR, and
it is involved in EMT, proliferation, apoptosis, and
inflammation.51 STAT3 is also central to mainte-
nance of self-renewal in cancer stem cells (CSCs).52
The STAT/JAK pathway is one of the critical targets
of cetuximab.53 Numerous other abnormalities have
been found to be prevalent in HNSCC; Tan et al has
addressed many of these in an excellent review.21
Given the great variety of genetic abnormalities
that have been identified in HNSCC, gene expression
profiles may offer greater accuracy for characteriza-
tion and diagnosis than analysis of single loci. Several
groups have established profiles that can differentiate
HNSCC from surrounding normal tissues. For exam-
ple, in a early study Chung et al identified four
subtypes of SCC based on gene expression profiles,
each with different survival and recurrence rates.54
They identified patterns that they classified as
(1) EGFR pathway subtype, (2) mesenchymal-
enriched subtype, (3) normal-epithelium–likesubtype, and (4) high-antioxidant enzyme subtype.
The EGFR group had the worst outcome. The second
subgroup had a high fibroblast component and
demonstrated evidence of EMT. The third group
demonstrated gene expression closest to normal
tonsillar epithelium and had the best outcome. The
fourth group demonstrated patterns similar to that
induced by exposure to cigarette smoking with high
levels of antioxidant enzymes being expressed.54
Clatot et al recently published a series in which they
used high-throughput reverse transcriptase polymer-
ase chain reaction to create a nine-gene model with
which they were able to classify patients with 90%
accuracy. Those in a cluster with higher expression
of the chemokine CXCL12 had significantly greater
disease-free survival compared to those in a low-
expression CXCL12 cluster. Among these nine genes,
a high-fold change in survival was seen in the group
comprised of CXCL12, SCL16A4 (monocarboxylate
transporter 4, MCT4), and carbonic anhydrase IX
(CA9). CXCL12 is an important cytokine in HNSCC
implicated in angiogenesis and other processes.55
SCL16A4/MCT4 is a lactate transporter that has been
shown to be overexpressed in response to hypoxia.
CA9 is also upregulated by hypoxia and functions to
regulate intracellular pH.56
A number of epigenetic changes have been found
to be common to HNSCC, including DNA methyla-
tion, histone modification, microRNA interference,
and small interfering RNA. Epigenetic regulation such
as methylation of CDK2a and other genes has been
shown to occur.57 Methylation of death-associated
protein kinase (DAPK) is associated with resistance
to anti-EGFR agents, like cetuximab.58 Jung et al
performed a combined analysis of the transcriptome,
methylome, and miRNome of metastatic HNSCC and
non-metastatic HNSCC and identified a signature that
correlated with lower survival and metastatic pheno-
type. The pathways involved in this group were
specifically related to cell–cell adhesion, EMT,
immune response, and apoptosis. For example, they
identified decreased expression of desmoglein 3 (DSG
3), a component of desmosomes critical for cell–cell
adhesion. Desmosomes also have been shown to have
tumor-suppressor function, and decreased expression
of DSG3 has been linked to a poor prognosis.59 They
also identified several elements significant in EMT,
including upregulation of vimentin and downregula-
tion of cytokeratin intermediate fibers and activation
of TGF-β–related EMT pathways. Analysis of miRNA
demonstrated upregulation of pathways related to
DDR and immune response.60CANCER-ASSOCIATED FIBROBLASTS
Normal squamous mucosal lining of the upper
aerodigestive tract is organized into distinct
J.M. Curry et al222compartments: the upper layer of differentiated
squamous or respiratory epithelial cells, a basal
epithelial layer, the underlying basement membrane,
and stromal layer. Fibroblasts are abundant in the
stroma and are the primary element responsible for
secretion of the basement membrane proteins. They
secrete structural proteins such as type IV collagen
and laminin and also produce numerous cytokines
and paracrine signals. Accordingly, tumor- or cancer-
associated fibroblasts (CAFs) are among the most
critical cellular elements of the TME. CAFs are
phenotypically altered fibroblasts, which are active
participants in the process of tumorigenesis, promot-
ing growth and metastasis.61
CAFs arise from the population of circulating
fibroblasts and co-evolve with the tumor developing
a distinct phenotype, and playing an active role in
carcinogenesis.62–64 They produce a variety of con-
tractile proteins, giving them an “active” phenotype.
Frequently, they demonstrate ultrastructural accu-
mulation of α-smooth muscle actin (α-SMA), charac-
teristic of myofibroblastic (MF) differentiation.65–67
In HNSCC, CAFs frequently have this MF phenotype
and are associated with dense collagen deposition
and stromal desmoplasia.68,69 CAFs are also charac-
terized by expression of integrin α6, which is critical
to cell adhesion and surface signaling. It complexes
to bind laminins, components of the extrcellular
matrix, and interacts with CDKN1A, altering cell
cycle progression. Lim et al demonstrated that
upregulation of α-SMA and integrin-α6 correlated
with worsened prognosis in oral cancer.70
CAFs express a variety of factors critical to
carcinogenesis, promoting cell motility by upregula-
tion of cytokines, such as paracrine motility factor,
hepatocyte growth factor (HGF), CXCL12, and
TGF-β.71 HGF secreted by CAFs has been shown to
promote invasion and angiogenesis in HNSCC and
esophageal SCC.65,72–74 CXCL12 binds to CXCR4;
this interaction plays a role in upregulation of MMP9,
EMT, and HIF-1α expression.75 TGF-β is a critical
element in the TME that serves numerous functions,
including immunosuppression. Additionally, CAFs
directly contribute to extracellular matrix remodel-
ing by secreting MMPs.76,77
Marsh et al demonstrated that the MF phenotype
seen in some oral carcinomas was strongly prognos-
tic of a negative outcome.78 This study evaluated 282
oral HNSCC specimens and found that the presence
of MF stroma was the strongest prognostic variable
assessed, as compared to surgical margins, extracap-
sular spread, and stage, among others. MF stroma
correlated with depth of invasion and with extrac-
apsular spread in nodal metastasis. Interestingly,
tumor-containing lymph nodes with extranodal
spread were also surrounded with MF stroma. In
oral and lingual carcinoma cell lines, Lin et al wereable to demonstrate increased proliferation in asso-
ciation with CAFs.79,80 In a mouse model using
heterotopic injection of HNSCC cells with normal
fibroblasts or CAFs, Wheeler et al demonstrated that
HNSCC cells with CAFs resulted in increased growth
of the primary tumor and nodal and distant meta-
stases compared to co-injection with normal
fibroblasts.61
CAFs are also critical to tumor metabolism. Recent
studies indicate that epithelial cancer cells may
derive nutrients from the CAFs via a coupled meta-
bolic mechanism. Cancerous cells induce glycolysis
in adjacent stromal cells such as CAFs and then use
their high-energy byproducts, such as lactate and
pyruvate.81 This is somewhat contrarian to the long
held belief of the Warburg effect, whereby tumors
are thought to rely on aerobic glycolysis to produce
energy for rapid growth. This has been labeled the
“reverse Warburg effect” and has been shown to be a
critical prognostic indicator in breast and other
human cancers. There is some evidence that sug-
gests this occurs in HNSCC as well.82THE IMMUNE RESPONSE IN THE TME
The persistent unresolved inflammation associ-
ated with cancer results in a eventual decay and
malfunction of the normal immune processes, which
in turn contributes to tumorigenesis through
immune tolerance and suppression and also to
angiogenesis and production of ROS. Essentially,
tumorigenesis is at least in part a byproduct of a
failure of the immune system.10,12,83,84 The adaptive
immune response contributes in a variety of ways to
tumorigenesis through the immune interactions in
the TME involving T lymphocytes, macrophages,
dendritic cells, and others.85
T Lymphocytes
T lymphocytes are the central component of the
anti-tumor response. They serve to initiate and regulate
the adaptive immune response and to elicit the cyto-
toxic response to tumors.85 There is evidence that
dysfunction occurs at the local, regional, and systemic
levels in HNSCC. While a strong lymphocytic host
presence at the tumor interface is indicative of an
adaptive immune response and correlates with an
improved survival,86–88 dysfunctional circulating T cells
and tumor-infiltrating T cells have been identified in
HNSCC, suggesting that tumors can suppress a previ-
ously intact local and systemic immune response.84,89–
93 Moreover on a regional level, metastatic lymph nodes
of HNSCC show significantly decreased levels of CD8þ
lymphocytes.87,94 Common functional deficits of
tumor-infiltrating T cells include: (1) absent or low
expression of a key molecule in the signaling receptor
Tumor microenvironment in HNSCC 223receptor chain (CD3ζ), (2) decreased proliferation in
response to mitogens, (3) inability to kill tumor cell
targets, (4) imbalance of their cytokine profile, and
(5) evidence of profound apoptotic features.84
Evasion of the adaptive response is executed
through a variety of mechanisms such as decreased
expression of major histocompatibility complexes
(MHC I) or induction of apoptosis in T cells.
Decreased expression of antigen-processing machi-
nery such as MHC glycoprotein allows escape of
subpopulations of tumor cells by avoiding activation
of cell mediated immunity.95–97 This mechanism has
been demonstrated in HNSCC whereby tumor cells
produce gangliosides, which downregulate MHC I.98
Another means of evading detection is to induce
apoptosis in cytotoxic T cells. The FasL receptor
mechanism is expressed by activated cytotoxic T cells,
which bind to FasL and typically result in triggering
the cytotoxic response. However, this also predis-
poses the T cell to apoptosis. Oral SCC cells have been
shown to contain membranous FasL-positive vesicles,
which trigger induction of T-cell apoptosis, circum-
venting the cytotoxic response.84,85,95
The cytotoxic response also can be dampened by
suppression. Intratumoral cytotoxic CD8þ T cells in
HNSCC show increased expression of programmed
death-1 (PD-1), a marker of suppressed function.87,99
Its ligand, programmed death receptor ligand-1 (PD-
L1), is a surface protein that blocks function of
T lymphocytes and is expressed on malignant oral
SCC cells and also on CAFs.100 Cho et al demon-
strated that increased PD-L1 expression resulted in
increased apoptosis of intratumoral CD8þ TILs.101
Moreover, cytokines like, TGF-β, IL-10, and others
allow local naı¨ve T cells to be triggered to become
suppressor T cells, while also exploiting the suppres-
sive functions of existing regulatory T cells.102PD-1 is
of particular interest in HPV-associated HNSCC, as a
lymphocytic infiltrate is one of the common features
of HPV-related OPSCC. Infiltration of the TME by PD-
1–positive T lymphocytes was correlated with
improved prognosis.103 While this is contrary to the
above findings, in the case of HPV-related OPSCC, the
PD-1–positive T lymphocytes, likely reflect an acti-
vated chronic immune response due to long-standing
viral infection.103ANTIGEN-PRESENTING CELLS AND TUMOR-
ASSOCIATED MACROPHAGES
Dendritic cells are specialized antigen-presenting
cells (APCs) common in the TME of HNSCC.84,98,104
They have a high a capacity for antigen capture and
also stimulate T-cell maturation. In contrast, when
exposed to TGF-β and IL-10, they can promote
immune tolerance and differentiation of CD4þ T
cells into suppressive regulatory T cells.84,105–107Langerhans cells are APCs located within the skin
and mucous membranes of the upper aerodigestive
tract. They detect antigens in the mucosa and then
migrate to regional lymph nodes where they initiate
a primary immune response. Some evidence sug-
gests that greater infiltration of HNSCC tumor sam-
ples with Langerhans cells correlates with improved
prognosis.84,108–110
Tumor-associated macrophages (TAMs) are
present with varying frequency in tumors, and are
common in HNSCC. TAMs are classified into two
varieties: proinflammatory (M1) and suppressive
(M2). Accordingly, studies in various cancers have
shown that TAMs can be associated with positive or
negative prognosis. M1 TAMs contribute to the anti-
tumor immune response via the production of
proinflammatory cytokines IL-12, IL-23, and
interferon-γ.84,111–113 While the M2 TAMs appear to
accumulate near blood vessels, promote angiogene-
sis,114,115 and produce a variety of suppressive
cytokines such as IL-10 and TGF-β. They also serve
to promote tissue remodeling and inhibit anti-tumor
cytotoxic effects of M1 TAMs.84,111–113,116 Data in
oral SCC suggest that TAMs are largely of the M2
type, as tumors with high levels of TAM infiltration
correlate with higher stage, lymph node metastasis,
and extracapsular spread.114,117,118 Lago Costa et al
demonstrated that macrophages were increased in
the TME and the peripheral blood in HNSCC, and
that samples with increased TAMs showed increased
levels of TGF-β and its correlated immunosuppres-
sive effects.119 They produce ROS, RNS, and prosta-
glandins (PGs), all of which can contribute to
inflammation and tumorigenesis. COX2 inhibitors
and nitric oxide synthase inhibitors (iNOS) have
been used to antagonize these inflammatory agents
and their cytokines.120,121 TAMs in HNSCC also
produce significant levels of macrophage migration
inhibitory factor (MIF), which is an inflammatory
cytokine that stimulates neutrophils. MIF recruits
neutrophils to the tumor via a CXCR2 mechanism
and then by feedback mechanisms increases inva-
siveness of the tumor cells.122 Neutrophils act on the
tumor in a variety of ways: inducing genetic insta-
bility via ROS, increasing angiogenesis via MMP9 and
VEGF, and increasing invasion via HGF.123THE BASEMENT MEMBRANE, INVASION, AND
MATRIX METALLOPROTIENASES
The basement membrane is barrier to tumor pro-
gression, and its degradation facilitates tumor invasion
and metastasis. For this to occur, cancer cells must
(1) develop motility, (2) alter cell–cell adhesion, and
(3) remodel the ECM.124 The basement membrane not
only serves as a structural framework for the overlying
epithelial cells but also provides paracrine signals that
J.M. Curry et al224affect their behaviors such as differentiation and migra-
tion.125 Many of the key elements of the basement
membrane, including collagen type IV and fibronectin,
have been shown to be disregulated in HNSCC. MMPs
are most important group of proteolytic enzymes used
by cancer to degrade the ECM. MMPs in normal tissues
are expressed in balance with their inhibitors to main-
tain a well-organized system. MMPs are upregulated by
NOTCH1 pathways, EGFR, TGF-β, HGF, and
granulocyte-macrophage colony-stimulating factor (GM-
CSF), which are commonly overexpressed in
HNSCC.126–129 Among the most commonly identified
metalloproteinases in HNSCC are MMP-2, MMP-9 and
membrane-bound MMP (MT-MMP). MMP-2 and MMP-9
are gelatinases and degrade collagen type IV, the most
critical step in degrading the BM.130 Increased levels of
MMP-2 and MMP-9 correlate with increased nodal
metastasis and poor prognosis.48 MMP-9 is the most
structurally complex and can degrade numerous ele-
ments of the TME, including elastin, fibrillin, laminin,
gelatin, and types IV, V, XI, and XVI collagen.131,132
MMPs were initially thought to be produced solely by
the tumor cell, but further investigation has shown
production also by the CAFs and surrounding inflam-
matory cells.48,133,134 CAFs are primarily responsible for
the increased production of MMP-2 in co-culture experi-
ments.130 MT-MMP is critical in activating MMP-2.135,136
There are numerous other significant MMPs, such as
MMP-13, which participates in angiogenesis increasing
the level of VEGF at the invasive front.137
Importantly, the functions of MMPs extend
beyond protein degradation and invasion, as they
target growth factors, growth factor receptors, and
cytokines.8 For example, MMP-9 also produces a
tolerogenic effect on dendritic APCs and also on
regulatory T cells.43 Release of MMP-9 results in
endothelial cell invasion and vessel formation.12,55
MMPs impact differentiation and maturation of bone
cells into osteoclasts, which is critical to the process
of bony invasion.138 HNSCC CSCs are characterized
by expression of CD44; CD44 is a surface protein
that functions as a receptor for hyaluronic acid and
also is the docking receptor necessary for MMP-9
function.139 Given the broad significance of MMPs
they represent a possible target for therapy directed
at the TME. Interestingly, quercitin, a flavonoid
isolated from onions, inhibits MMP-2 and -9
pathways.140TGF-b AND EPITHELIAL–MESENCHYMAL
TRANSITION
A number of chemokines and cytokines provide
critical paracrine signaling in the TME; here we focus
on TGF-β, as it broadly impacts many cellular behav-
iors in the TME. TGF-β has both growth-promoting
and -suppressive effects on cells, and for some timethe role of TGF-β in malignancy had been controver-
sial. It typically inhibits epithelial cell proliferation
and promotes secretion of matrix proteins and
proteases. Currently it is understood to act as a
tumor-suppressor early in tumorigenesis, then in later
phases it enhances the malignant phenotype.141 TGF-
β primarily acts through the SMAD family of tran-
scription factors and works in concert with mitogen-
activated protein kinases (MAPKs), which regulate
diverse cellular activities such as mitosis, differentia-
tion, proliferation, cell survival, and apoptosis. Dys-
regulation of TGF-β in malignancy occurs through
several mechanisms, including loss of response to its
ligand, defects in the transduction pathway, and
others.141 Oral SCC has been shown to be resistant
to the suppressive effects of TGF-β, secondary to
downregulation of TGF-β receptor II (TBRII).141,142
TGF-β is a primary factor triggering EMT in
HNSCC. EMT contributes to invasion allowing for
enhanced mobility via expression of a protein expres-
sion patterns more characteristic of a mesenchymal
phenotype. Once established, nests of metastatic
tumor can transition back to a phenotype recapitulat-
ing the original tumor in a distant site. EMT is
mediated through disruption of epithelial cell junc-
tions, remodeling of the actin cytoskeleton, and
upregulation of mesenchymal markers like vimentin
and firbonectin.141 TGF-β pathways as well as those
triggered by the inflammatory cytokines TNF-α and
IL-6 converge upon STAT3, upregulating it.52,143,144
STAT3 proteins are commonly overexpressed in
HNSCC. STAT3 interacts with Twist, Snail, and Slug
(Snail2), transcription factors that contribute to EMT
in various cancers.52,144,145 Twist increases expres-
sion of N cadherin, a marker of a mesenchymal
motile phenotype, and decreases expression of E
cadherin, a marker of an epithelial phenotype. Slug
also decreases expression of E-cadherin. Loss of
E-cadherin and gained expression of N-cadherin is
critical to invasion and is referred to as cadherin
switching.146 Prime et al were able to demonstrate
morphologic evidence of EMT and cadherin switch-
ing after several days exposure to TGF-β.138,147
Emerging evidence suggests that EMT is fundamental
to gaining “stemness” or the transition of cancer cells
to becoming CSCs. CSCs are thought to serve as a
fountainhead for tumors as they give rise to the
remaining population of tumor cells, and contribute
to treatment resistance. CSCs accumulate at the
invasive front and perivascular spaces and are demar-
cated by expression of markers such as CD133 and
CD44, and by aldehyde dehydrogenase activity.139
On the surface of CSCs, CD44 interacts with MMP-9
and this allows for proteolytic activation of TGF-β.148
TGF-β extends beyond the epithelial cancer cells of
a tumor, and many of the effects have been described
above. Lewis et al showed that TGF-β produced at the
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phenotype in primary fibroblasts. They also showed
that this effect resulted in secretion of HGF by
myofibrblasts, which in turn promoted invasion
through the basement membrane. TGF-β serves to
inhibit TH1 lymphocytes and cytotoxic T lympho-
cytes and the functions of natural killer cells.84ANGIOGENESIS, INFLAMMATION, AND
HYPOXIA
Small tumor deposits of 1–3 mm can be supplied
by diffusion of nutrients from the surrounding tissue;
beyond this, the tumor is dependent on angiogenesis
to supply its needs.149 A number of studies have
shown that angiogenesis is correlated with tumor
aggression.48,150–154 HNSCC often has large hypoxic
areas of tumor necrosis where growth exceeds
angiogenesis.155–157 Hypoxic response and inflam-
mation are driving forces in angiogenesis.12,158 More-
over, CSCs in HNSCC appear to be concentrated
along the invasive front of the tumor and in the
perivascular niche, an area within 100 μm of the
microvasculature. A variety of factors in the TME,
such as VEGF, NF-κB, and HIF-1α play central roles in
this process.
VEGF enhances endothelial growth, migration of
endothelial precursors, and their differentiation. High
VEGF expression in oral SCC has been correlated
with a poor prognosis, and a recent meta-analysis
suggested that VEGF overexpression could be a
useful prognostic marker.159 VEGF binds to its recep-
tor, VEGFR1 in tumor cells, and induces expression
of Bcl-2, inducing chemokines like CXCL1 and
CXCL8. CXCL1 and CXCL8 promote endothelial cell
proliferation and survival.160 Endothelial cells in turn
produce factors like EGF, which significantly increase
tumor cell survival and migration.161 VEGF and other
angiogenic factors such as IL-6 and IL-8 are increased
by a number of chemokines such as CXCL12, which
binds to chemokine receptors CXCR2 and CXCR4.
High CXCR2 and CXCR4 levels have been shown to
be associated with increased microvessel density
within tumors.55,77,162
Chronic inflammation of the TME contributes to
tumor progression through a variety of mechanisms,
including production ROS and angiogenic factors.
NF-κβ is an inflammatory signal transcription factor
playing a variety roles in invasion, proliferation, and
angiogenesis. Constitutive activation NF-κβ results in
overexpression of a variety of factors, including Il-6,
IL-8, and VEGF.43
There are many downstream inflammatory
markers expressed as a result of NF-κβ and other
mechanisms, such as cyclooxygenases like COX-2.163
COX enzymes catalyze the production of PGs and
likely are the rate-limiting step in their synthesis.COX-2 is usually overexpressed in inflammation and
preneoplastic lesions. PGs are increased in HNSCC,
and PGE2 promotes invasion and angiogenesis and
inhibits apoptosis of cancer cells. COX-2 acts on
VEGF, fibroblast growth factor, and MMPs and is also
pro-angiogenic. COX-2 levels have been found to be
prognostic and selective COX-2 inhibitors have
been shown to increase the efficacy of radio-
therapy in vitro.51,164 NF-κβ is the target of many
therapeutic interventions, such as curcumin, n-acetyl
cysteine (NAC), epigallocatechin gallate (EGCG), and
others.5
Intratumoral hypoxia is a key characteristic of
HNSCC, and is a negative prognostic factor, contri-
buting to both chemotherapy and radiotherapy resist-
ance. Intratumoral hypoxia is generally accepted to
be a pO2o10 mm Hg, and intratumoral pO2 levels
≤2.5 mm Hg correlate with a worsened prognosis, as
does the overall volume of hypoxic tumor at the
primary site.165 HIF-1α is the most important factor
induced in adaptive response to hypoxia, and ele-
vated expression is also directly associated with a
poor prognosis.166 This transcription factor interacts
with more than 100 genes to alter expression of
VEGF, CA9, lysyl oxidase, and many others.48,167 It
has been shown to alter cellular metabolism, and to
increase lymphatic vessel density and blood vessel
density in oral SCC.168,169 CA9 functions to regulate
pH homeostasis and alter the uptake of chemother-
apeutic drugs, and also is purported to play a role in
proliferation and cell adhesion.165,170 Lysyl oxidase
catalyzes the crosslinking of collagens and elastins,
and overexpression increases microvascular den-
sity.171,172 Agents such as reseveratrol, EGCG and
others may act by promoting degradation of HIF-
1α.173–175 Resveratrol has been shown to decrease
expression of HIF-1α and VEGF in vitro.176METABOLISM IN THE TME
Cancer cells have high bioenergetic requirements
needed to maintain tumor growth. Tumor cells in
culture have long been demonstrated to rely heavily
on glycolysis with decreased, dysfunctional, or absent
mitochondrial OXPHOS. Reliance on glycolysis in the
presence of oxygen is referred to as the Warburg
effect.177 This results in the generation of less ATP
than OXPHOS and yields high levels of pyruvate and
lactate. This is somewhat counterintuitive as there is
such a high bioenergetics requirement, yet OXPHOS
is a more efficient means of energy generation than
glycolysis. Thus it is unclear why tumor cells would
thrive with a less efficient mechanism. It has been
hypothesized that glycolysis may confer a growth
advantage.178–180 Some normal, highly proliferative
cells, such as lymphocytes, favor aerobic glycolysis
over oxidative metabolism, providing a rationale for
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in critical components of the OXPHOS pathway, such
as the mitochondrial B-catalytic subunit of Hþ-ATP
synthase.182,183 Furthermore, when glycolytic flux is
high, the ATP yield can exceed that produced by
OXPHOS.182,183 Additionally, the intermediates of
glycolytic metabolism can provide substrates for
amino acid, fatty acid, and nucleotide synthesis.167
The metabolic pressures induced by hypoxia in the
setting of rapid growth may then in turn select for
tumor cells which favor glycolytic metabolism even
in the presence of oxygen, as is suggested by the
frequent overexpression of HIF-1α in many cancers.
Hypoxic induction of HIF-1α favors this process
specifically inducing pyruvate dehydrogenase kinase
(PDK) and lactate dehydrogenase a (LDH-A). PDK
inactivates pyruvate dehydrogenase preventing
import of pyruvate to the mitochondria. LDH-A
restores NAD positivity and also uses pyruvate in
the cytosol, which together can reduce electron flow
though OXPHOS and also reduce oxidative stress.
Additionally, glycolytic metabolism results in the
acidotic efflux into the TME that assists in breakdown
of the ECM and kills non-adapted normal cells.184
However, this is not likely the whole picture:
much recent evidence suggests that a metabolic
symbiosis exists within tumors cell between differ-
ent populations. Feron has likened this to the
coupling between fast and slow-twitch muscle
fibers. Fast-twitch glycolytic fibers release lactate
that is then taken up and utilized by slow twitch
fibers. MCT1 is a high-affinity transporter of lactate,
which mediates influx into the cell; MCT4 is a low-
affinity transporter of lactate, which primarily medi-
ates efflux of lactate from cells. These transporters
couple cancer cells, so that hypoxic cells maintain
functioning glycolytic metabolism while aerobic
tumor cells recycle and utilize lactate and other
high-energy substrates produced by them. A similar
process in cancer would allow for an efficient intra-
tumoral metabolic coupling mechanism between
oxygenated cells and hypoxic cells.179
Additional evidence favors multicompartmental
metabolism between the cancer cells and CAFs.
Numerous co-culture experiments and in situ tumor
analyses have demonstrated this effect in breast and
other cancers.11,81,185 This work has brought to light
a “reverse Warburg effect”, where oxidative stresses
exerted by tumor cells induce aerobic glycolysis and
autophagy in CAFs. This, in turn, results in increased
levels of intermediate catabolites such as lactate,
glutamine, and ketone bodies. These catabolites are
released into the TME and used for OXPHOS in
carcinoma cells. This metabolically enriches the TME
and creates an environment that favors growth,
apoptosis resistance, invasion, and metastasis.81,185
This is Paget’s seed and soil hypothesis, aphenomenon that may have been unnoticed in
previous homotypic culture experiments.11
Most studies on HNSCC cellular metabolism sug-
gest that the carcinoma cells are highly glycolytic
with high L-lactate generation, yet recent studies
suggest that metabolic heterogeneity and metabolic
coupling occur. Most HNSCC cells generate signifi-
cantly higher levels of lactate compared with normal
human oral keratinocytes (NHOK), although several
cell lines generate significantly lower lactate levels
than NHOKs.186 It has been postulated that the cells
with decreased lactate production have increased
lactate uptake via MCTs, allowing them to utilize
OXPHOS.186 When some HNSCC cell lines that are
typically glycolytic are supplemented with excess
pyruvate, some of the effects were reversed, which
suggests that OXPHOS is important to support
HNSCC cell proliferation in the presence of a
catabolite-rich microenvironment.187 High tumor
lactate concentrations in HNSCC are associated with
subsequent nodal and distant metastatses.188,189
In our previously published work on oral SCC, we
demonstrated evidence of this multicompartment
model of metabolism. We have suggested that there
may be three metabolic compartments in HNSCC,
where the leading tumor edge relies on OXPHOS
and the deeper layers of the tumor are more
glycolytic (aerobic or anaerobic) and tumor stroma
represents a third compartment undergoing aerobic
glycolysis (Figure 2). This was demonstrated through
high expression of MCT4 in the stroma and deeper
tumor, while MCT1 was more highly expressed by
the leading tumor edge. We also confirmed OXPHOS
in the leading tumor edge with assays for TOMM20
and LDHb, both functional markers for mitochon-
drial metabolism. This pattern of metabolic coupling
was demonstrated in a subset of our oral SCC
patients, and correlated with aggressive behavior
including a worsened disease-free survival and peri-
neural invasion. Interestingly, it also correlated with
increased specific uptake values (SUV) on positron
emission tomography/computed tomography. We
further tested this metabolic coupling theory with
a squamous cell carcinoma line co-culture experi-
ment. Using immortalized squamous cell lines we
were able to generate two divergent SCC popultions,
one RAS-dependent and another NF-κB–dependent.
These cell lines were each able to induce metabolic
reprogramming of CAFs via oxidative stress. This
resulted in a lactate shuttling process that feeds the
cancer cells fueling anabolic growth via and MCT1/
MCT4 metabolic couple between the tumor and the
stroma. Interestingly, this model also demonstrated
that the CAFs protected the cancer cells against
oxidative stress by reducing oxidative stresses within
the carcinoma cells. RAS-transformed cells were able
to reprogram adjacent epithelial cells, as well as
Figure 2. Metabolic coupling in HNSCC. The leading edge of the tumor relies on OXPHOS while the inner compartment
and CAFs rely on glycolytic metabolism. Higher expression of MCT1 is seen in the leading tumor edge, while higher
expression of MCT4 is seen in the central compartment and stromal CAFs.
Tumor microenvironment in HNSCC 227fibroblasts, suggesting that cancer cells can subju-
gate either group.
MCT4 may represent a possible target for meta-
bolic interruption and uncoupling of the tumor and
stroma. In an animal model, we were able to
demonstrate that NAC was able to selectively inhibit
MCT4 induction in CAFs, halting mitochondrial bio-
genesis in cancer cells but not in normal epithelial
cells. This may allow targeted therapy that selec-
tively starves cancer cells. MCT1 also has been
proposed as a possible target to prevent uptake of
lactate, forcing aerobic cells to use glucose and
depriving or decreasing availability to hypoxic
cells.167 In fact, the MCT1 inhibitor, a-cyano-hydroxycinnamate has been shown to slow tumor
growth and potentiate the effect of radiotherapy in
MCT1-expressing tumors in mice.179,184
Hypoxia contributes to chemotherapy and radio-
therapy resistance.155 Inhibition of HIF-1α can pre-
vent the induction of the hypoxic response blocking
angiogenesis.190 Zhang et al inhibited HIF-1α with
siRNA and oligonucleotides, which increased apop-
tosis in oral SCC.191 The EGFR inhibitor cetuximab
blocks downstream signaling activated by EGFR; this
triggers G1 phase arrest and can also trigger apop-
tosis.192 In addition, it has been shown to down-
regulate HIF-1α; this, in turn, downregulates their
LDH-a and glycolytic potential. This inhibition of
J.M. Curry et al228glycolytic potential leads to inhibition of
proliferation.192
Metformin is a commonly used antihyperglycemic
drug in type 2 diabetics and has been proposed as a
potential anticancer therapy also that may impact
tumor metabolism in the TME. Metformin has been
shown to inhibit cancer cell proliferation in several
human cancers, such as gastric, medullary thyroid,
breast, and pancreatic cancers.193–196 Epidemiologic
studies also have shown significant effects from
metformin use in diabetics, lowering the risk of
cancer incidence and mortality.197 In oral SCC, Luo
et al demonstrated that metformin blocked cell cycle
progression at the G0/G1 phase and induced apop-
tosis. Metformin triggered alterations in multiple
other pathways as well: increasing activation of the
adenosine monophosphate (AMP) kinase pathway,
suppressing the mammalian target of rapamycin
(mTOR) pathway, decreasing cyclin D1 levels and
retinoblastoma (Rb) phosphorylation, and downregu-
lating Bcl 2.198 They also were able to demonstrate
in vivo evidence of increased apoptosis in a xenograft
model. While this study demonstrated various effects
on the cell cycle; the metabolic effects of metformin
on cancer have yet to be investigated.CONCLUSION
Many elements of the TME beyond the cancerous
epithelial cells impact progression of HNSCC.
Genetic alterations induced by tobacco and alcohol
or the HPV virus initiate the sequence of events that
trigger transformation of stromal cells, immune sup-
pression, and chronic inflammation. In turn,
unchecked growth, invasion, and metastasis prevail.
The complexity of these processes reveals that the
long-held notion of “condemned mucosa” actually
reflects a “condemned tissue” comprised of many cell
types which have co-evolved during tumorigenesis.
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